The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
Open accessAbstract
Increased expression of CD47 has been reported to enable cancer cells to evade phagocytosis by macrophages and to promote the cancer stem cell phenotype, but the molecular mechanisms regulating CD47 expression have not been determined. Here we report that hypoxia-inducible factor 1 (HIF-1) directly activates transcription of the CD47 gene in hypoxic breast cancer cells. Knockdown of HIF activity or CD47 expression increased the phagocytosis of breast cancer cells by bone marrow-derived macrophages. CD47 expression was increased in mammosphere cultures, which are enriched for cancer stem cells, and CD47 deficiency led to cancer stem cell depletion. Analysis of datasets derived from thousands of patients with breast cancer revealed that CD47 expression was correlated with HIF target gene expression and with patient mortality. Thus, CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“hypoxic tumor cells evade innate immune recognition through the up-regulation of CD47, a cell surface molecule that interacts with signal regulatory protein alpha (SIRP α) on the surface of macrophages to block phagocytosis”
From Hypoxic control of metastasis (2016) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
7 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedSamanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
Self-citationRetractedRETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
Self-citationRetractedZhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326
Self-citationRetractedRETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
Self-citationRetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
Self-citationRetractedGilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
Self-citationRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Cited by
Sorted by citations
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,101
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,718
Rankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., He, X., & Semenza, G. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602883113 · Cited by 977
Self-citationHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Self-citationPhagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 937
Self-citationThe role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 760
Hypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 626
Self-citationCancer Stem Cells: The Architects of the Tumor Ecosystem
Prager, B. C., Xie, Q., Bao, S., & Rich, J. N. (2019) · Cell stem cell · doi:10.1016/j.stem.2018.12.009 · Cited by 608
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 576
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., Li, Y., Nepovimová, E., Heger, Z., Wu, W., Kuča, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 518
Targeting CD47 for cancer immunotherapy
Jiang, Z., Sun, H., Yu, J., Tian, W., & Song, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01197-w · Cited by 349
The Role of the Extracellular Matrix in Cancer Stemness
Nallanthighal, S., Heiserman, J. P., & Cheon, D.-J. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00086 · Cited by 344
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Self-citationEmerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 291
The role of hypoxia‐inducible factor 1 in tumor immune evasion
Li, Y., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimová, E., Wu, Q., & Kuča, K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 276
Functions of Immune Checkpoint Molecules Beyond Immune Evasion
Zhang, Y., & Zheng, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_9 · Cited by 267
Zhang, C., Zhi, W. I., Lu, H., Samanta, D., Chen, I., Gabrielson, E., & Semenza, G. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11743 · Cited by 266
Self-citationEmerging roles of aerobic glycolysis in breast cancer
Wu, Z., Wu, J., Zhao, Q., Fu, S., & Jin, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02187-8 · Cited by 264
Hypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264
Hypoxia: Signaling the Metastatic Cascade
Rankin, E. B., Nam, J.-M., & Giaccia, A. J. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.006 · Cited by 249
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Betancur, P. A., Abraham, B. J., Yiu, Y. Y., Willingham, S. B., Khameneh, F., Zarnegar, M. A., Kuo, A. H., McKenna, K. M., Kojima, Y., Leeper, N. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14802 · Cited by 243
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Self-citationNoman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaı̈b, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 220
Spatially fractionated radiation therapy: History, present and the future
Yan, W.-S., Khan, M. K., Wu, X.-D., Simone, C., Fan, J.-J., Gressen, E., Zhang, X., Limoli, C., Bahig, H., Tubin, S., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.10.004 · Cited by 210
HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
Zhao, Y., Xing, C., Deng, Y., Ye, C., & Peng, H. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.039 · Cited by 231
CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
Jia, X., Yan, B., Tian, X., Liu, Q., Jin, J., Shi, J., & Hou, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60782 · Cited by 207
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 203
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W., & Wong, C. C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 187
The Immunology of Hormone Receptor Positive Breast Cancer
Goldberg, J., Pastorello, R., Vallius, T., Davis, J. A., Cui, Y. X., Agudo, J., Waks, A. G., Keenan, T. E., McAllister, S. S., Tolaney, S. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674192 · Cited by 182
Wang, S., Wu, Q., Chen, T., Su, R., Pan, C., Qian, J., Huang, H., Yin, S., Xie, H., Zhou, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.011 · Cited by 168
Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment
Lu, H., Chen, I., Shimoda, L. A., Park, Y., Zhang, C., Tran, L., Zhang, H., & Semenza, G. L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.001 · Cited by 173
Self-citationKabakov, A. E., & Yakimova, A. O. (2021) · Cancers · doi:10.3390/cancers13051102 · Cited by 170
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer
Zhao, H., Wang, J., Kong, X., Li, E., Liu, Y., Du, X., Kang, Z., Tang, Y. C., Kuang, Y., Yang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep29719 · Cited by 152
CD47–SIRPα-targeted therapeutics: status and prospects
Maute, R. L., Xu, J., & Weissman, I. L. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100070 · Cited by 159
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 146
Bian, Z., Shi, L., Guo, Y.-L., Lv, Z., Tang, C., Niu, S., Tremblay, A., Venkataramani, M., Culpepper, C. D., Li, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521069113 · Cited by 140
Tumor microenvironment-mediated chemoresistance in breast cancer
Velaei, K., Samadi, N., Brazvan, B., & Rad, J. S. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 138
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 142
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells
Lupia, M., Angiolini, F., Bertalot, G., Freddi, S., Sachsenmeier, K. F., Chisci, E., Kutryb-Zając, B. A., Confalonieri, S., Smolenski, R. T., Giovannoni, R., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.02.009 · Cited by 135
Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy
Zheng, Z., Su, J., Bao, X., Wang, H., Bian, C., Zhao, Q., & Jiang, X. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1247268 · Cited by 145
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 139
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
Role of hypoxia in cellular senescence
Gao, H., Nepovimová, E., Heger, Z., Valko, M., Wu, Q., Kuča, K., & Adam, V. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106841 · Cited by 137
Maintenance of redox homeostasis by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2017) · Redox Biology · doi:10.1016/j.redox.2017.05.022 · Cited by 127
Self-citationLan, J., Lu, H., Samanta, D., Salman, S., Lü, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 127
Self-citationHypoxic tumor microenvironment: Implications for cancer therapy
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220934038 · Cited by 134
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 121
The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells
Kim, H., Lin, Q., Glazer, P. M., & Yun, Z. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0944-8 · Cited by 122
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 125
Boreel, D. F., Span, P. N., Heskamp, S., Adema, G. J., & Bussink, J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3913 · Cited by 120
Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Agarwal, P., Hwang, B.-J., Acharya, C. R., Shuptrine, C. W., Wang, T., Wei, J.-P., Yang, X. Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131882 · Cited by 120
Regulation of CD47 expression in cancer cells
Huang, C.-Y., Ye, Z.-H., Huang, M., & Lu, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100862 · Cited by 128
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
Brooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 110
Putting the brakes on phagocytosis: “don't-eat-me” signaling in physiology and disease
Kelley, S. M., & Ravichandran, K. S. (2021) · EMBO Reports · doi:10.15252/embr.202152564 · Cited by 117
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Terry, S., Buart, S., & Chouaı̈b, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01625 · Cited by 111
Hu, H., Cheng, R., Wang, Y., Wang, X., Wu, J., Kong, Y., Zhan, S., Zhou, Z., Zhu, H., Yu, R., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153470 · Cited by 111
Self-citationCD133, Selectively Targeting the Root of Cancer
Schmohl, J., & Vallera, D. A. (2016) · Toxins · doi:10.3390/toxins8060165 · Cited by 114
Kaur, S., ELKAHLOUN, A. G., SINGH, S. P., Chen, Q., Meerzaman, D. M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7100 · Cited by 107
Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy
Ma, Z., Wang, L. Z., Cheng, J.-T., Lam, S. T., Ma, X., Xiang, X., Wong, A. L., Goh, B. C., Gong, Q., Sethi, G., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7935 · Cited by 103
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 102
Targeting CD47 in Sézary syndrome with SIRPαFc
Johnson, L. D. S., Banerjee, S., Kruglov, O., Viller, N. N., Horwitz, S. M., Lesokhin, A. M., Zain, J. M., Querfeld, C., Chen, R., Okada, C. Y., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030577 · Cited by 99
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaı̈b, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 102
Liu, Y., Wu, J., Huang, W., Weng, S., Wang, B., Chen, Y., & Wang, H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02366-0 · Cited by 98
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
Yang, H., Shao, R., Huang, H., Wang, X., Rong, Z., & Lin, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2332 · Cited by 97
Liu, X., Xie, P., Hao, N., Zhang, M., Liu, Y., Liu, P., Semenza, G. L., He, J., & Zhang, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109144118 · Cited by 93
Self-citationMitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis
Wu, H., Wang, T., Liu, Y., Li, X., Xu, S., Wu, C., Zou, H., Cao, M., Jin, G., Lang, J., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01768-8 · Cited by 91
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 88
Regulation of cancer stem cells in triple negative breast cancer
Fultang, N., Chakraborty, M., & Peethambaran, B. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.106 · Cited by 101
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
CD47: the next checkpoint target for cancer immunotherapy
Feng, R., Hai, Z., Xu, J., & Shen, C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103014 · Cited by 87
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Choi, Y., Seok, S. H., Yoon, H. Y., Ryu, J. H., & Kwon, I. C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115306 · Cited by 92
Role of hypoxia inducible factor-1 in cancer stem cells (Review)
Zhang, Q., Han, Z., Zhu, Y., Chen, J., & Li, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11655 · Cited by 90
Elanany, M. M., Mostafa, D., & Hamdy, N. Μ. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121997 · Cited by 86
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Khouzam, R. A., Venkatesh, G. H., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaïb, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 84
Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
Badrinath, N., & Yoo, S. Y. (2019) · Cancers · doi:10.3390/cancers11030310 · Cited by 84
Deshmukh, S. K., Srivastava, S. K., Poosarla, T., Dyess, D. L., Holliday, N. P., Singh, A. P., & Singh, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.68 · Cited by 85
Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
Grégoire, H., Roncali, L., Rousseau, A., Chérel, M., Delneste, Y., Jeannin, P., Hindré, F., & Garcion, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00368 · Cited by 88
Deciphering the role of CD47 in cancer immunotherapy
Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., Shi, Y., Wang, P., & Fang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.10.009 · Cited by 87
Hypoxia-tropic Protein Nanocages for Modulation of Tumor- and Chemotherapy-Associated Hypoxia
Huang, X., Zhuang, J., Chung, S. W., Huang, B., Halpert, G., Negrón, K., Sun, X., Yang, J., Oh, Y., Hwang, P. M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b05399 · Cited by 84
Noman, M. Z., Moer, K. V., Marani, V., Gemmill, R. M., Tranchevent, L.-C., Azuaje, F. J., Muller, A., Chouaı̈b, S., Thiery, J. P., Berchem, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1345415 · Cited by 80
3D culture technologies of cancer stem cells: promising ex vivo tumor models
Zhang, C., Yang, Z., Dong, D.-L., Jang, T., Knowles, J. C., Kim, H., Jin, G., & Xuan, Y. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731420933407 · Cited by 82
Self-citationTumor cell-associated immune checkpoint molecules – Drivers of malignancy and stemness
Marcucci, F., Rumio, C., & Corti, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.006 · Cited by 81
Artificial Natural Killer Cells for Specific Tumor Inhibition and Renegade Macrophage Re‐Education
Zou, M., Liu, W., Gao, F., Bai, X., Chen, H., Zeng, X., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201904495 · Cited by 76
Radiotherapy: An immune response modifier for immuno-oncology
Martino, M. D., Daviaud, C., & Vanpouille‐Box, C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101474 · Cited by 81
You, L., Zhao, Y., Kuča, K., Wang, X., Olekšák, P., Chrienová, Ž., Nepovimová, E., Jacevic, V. M., Wu, Q., & Wu, W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03030-2 · Cited by 78
The development of small-molecule inhibitors targeting CD47
Yu, W., Ye, Z.-H., Chen, X., Shi, J.-J., & Lu, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.003 · Cited by 76
Li, Y., Lu, S., Xu, Y., Qiu, C., Jin, C., Wang, Y., Liu, Z., & Kong, B. (2017) · PubMed Central · Cited by 74
Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy
Koukourakis, M. I., & Giatromanolaki, A. N. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1490041 · Cited by 74
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy
Li, Z., Li, Y., Gao, J., Fu, Y., Hua, P., Jing, Y., Cai, M., Wang, H., & Tong, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119150 · Cited by 76
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71
Self-citationHypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity
Qian, J., & Rankin, E. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_3 · Cited by 73
Cellular Plasticity in Breast Cancer Progression and Therapy
Kong, D., Hughes, C. J., & Ford, H. L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00072 · Cited by 73
Metadata
- Authors
- Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-10-28
- Volume
- 112
- Issue
- 45
- Pages
- E6215-23
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4653179
- OpenAlex
- W1853160207
- Cited by
- 420
- References
- 62
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 62 · 2023: 46 · 2022: 57 · 2021: 48 · 2020: 52 · 2019: 29 · 2018: 31 · 2017: 17 · 2016: 21 · 2015: 1
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-25)
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society (122437-RP-12-090-01-COUN)
- U.S. Department of Defense (W81XWH-12-1-0464)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- HIF-1, CD47, breast cancer, phagocytosis evasion, macrophages, cancer stem cells, hypoxia, transcriptional regulation, mammospheres, patient mortality, prognostic factors
- MeSH terms
- Analysis of Variance, Breast Neoplasms, Female, Humans, Luciferases, Phagocytosis, Neoplastic Stem Cells, Immunoblotting, Gene Expression Regulation, Neoplastic, DNA Primers, Tumor Escape, RNA, Small Interfering, Cell Line, Tumor, Chromatin Immunoprecipitation, Hypoxia-Inducible Factor 1, CD47 Antigen, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
